One-Day TMS
condenses the FDA-cleared intermittent theta-burst stimulation (iTBS) protocol into a carefully spaced series of
20 sessions delivered within a single day. While this
accelerated schedule is not FDA-approved, the
iTBS protocol itself is FDA-cleared for depression, and
early research supports the feasibility, safety, and potential efficacy of condensed treatment formats.
The ONE-D model draws from emerging clinical data, including a 2025 open-label case series of 32 adults with depression treated with a single-day 20-session protocol combined with neuroplasticity-enhancing medication. This study found the regimen to be
“feasible, safe, well tolerated, and associated with clinically meaningful improvement”* with effects sustained at 3–6 months.
This format may be ideal for individuals who want a highly time-efficient treatment experience or who face complex scheduling demands—and who want to pursue a non-medication, neuroscience-guided pathway with close clinical supervision.
Accelerated TMS is supported by a growing body of neuroscience research showing that multiple iTBS sessions delivered within a condensed timeframe may deliver attractive convenience with similar efficacy.
Note that although the evidence is promising, accelerated TMS schedules—including single-day protocols—are not FDA-approved and remain investigational.
*Source: ONE-D case series (2025)
